Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for L1CAM drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | L1CAM ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View L1CAM Products |
| Gene Delivery | L1CAM Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based conformation assays. |
View L1CAM Products |
| Benchmark Ab | Anti-L1CAM Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View L1CAM Products |
| Validator | L1CAM siRNA Set For target knockdown verification and specificity validation. |
View L1CAM Products |
| Related Target A | ADAM10 Primary shedding protease responsible for generating soluble L1CAM (sL1CAM) decoy receptors. |
View ADAM10 Products |
| Related Target B | NCAM1 Subfamily homolog used for counter-screening to ensure off-target safety. |
View NCAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding-resistant epitope screening | Truncated and full-length L1CAM ECD-Fc proteins with verified molecular weight and intact glycosylation profiles. |
| Subfamily counter-screening (NCAM1/ALCAM) | Homolog panel proteins strictly verified by mass spectrometry to guarantee zero cross-contamination. |
| Lack of clinical-grade positive controls | Sequence-verified biosimilar antibodies synthesized with mammalian expression systems. |
| Conformational cell-surface assays | High-titer lentiviral vectors for stable cell line generation, avoiding transient transfection variability. |
Live L1CAM/CD171 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for L1CAM/CD171 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glycosylation profiles and shedding-resistant epitopes to overcome systemic toxicity and decoy receptor interference.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Oncomatryx, NBE-Therapeutics | Ovarian Cancer, Pancreatic Cancer, Triple-Negative Breast Cancer (TNBC) | Internalization Assay (Requires HEK293-expressed, native-glycosylated ECD-Fc) |
| CAR-T Therapy | City of Hope, Seattle Children's Hospital | Glioblastoma, Neuroblastoma | Target Density & Cell-surface Conformation Validation (Requires Lentivirus for Stable Cell Lines) |
| Bispecific Antibody | Academic Institutions, Biotech Startups | Metastatic Solid Tumors | Dual-binding Affinity Verification (Requires high-purity L1CAM and co-target proteins) |